Sarah Ketterer
Causeway Capital Management
Sarah Ketterer Puma Biotechnology Inc stake
total: 372
Causeway Capital Management PBYI trades
- Total transactions:
- 3
- New positions:
- 1
- Sold out:
- 1
- Reduced:
- 1
- Held since:
- 2025 Q1
- Held for:
- 4 quarters
- Latest activity:
- 2026 Q1
According to 2026 Q2 report, Sarah Ketterer doesn't hold any Puma Biotechnology Inc (PBYI) shares. To date, the estimated cost basis is nearly $2.96 for "buy" trades and estimated average "sell" price is $5.95. Causeway Capital Management first purchased PBYI in 2025 Q1, initially acquiring 14,095 shares. Since the initial investment in Puma Biotechnology Inc (PBYI), Causeway Capital Management has made 2 more transactions.
When did Sarah Ketterer sell Puma Biotechnology Inc (PBYI)?
Sarah Ketterer sold off the entire Puma Biotechnology Inc (PBYI) position in 2026 Q1.
When did Sarah Ketterer buy Puma Biotechnology Inc (PBYI)?
Sarah Ketterer first invested in Puma Biotechnology Inc (PBYI) in 2025 Q1 at the reported quarter-end price of $2.96 per share.
What's the cost basis of Causeway Capital Management's PBYI stake?
The estimated cost basis for Puma Biotechnology Inc (PBYI) stake is around $2.96 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $2.96
- Weighted AVG sell price:
- $5.95
Sarah Ketterer's historical trades in Puma Biotechnology Inc
3 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
0.00%
|
0
|
$5.95
|
|
-100% (-13,310)
|
-0%
|
|
2025 Q4
|
0.00%
|
13,310
|
$5.95
|
$79,195
|
-5.57% (-785)
|
-0%
|
|
2025 Q1
|
0.00%
|
14,095
|
$2.96
|
$41,721
|
new
|
+0%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.